Clinical Trial Detail

NCT ID NCT02041533
Title An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Bristol-Myers Squibb
Indications

non-small cell lung carcinoma

Therapies

Nivolumab

Paclitaxel

Cisplatin

Pemetrexed

Carboplatin

Gemcitabine

Age Groups: adult

Additional content available in CKB BOOST